{"id":32928,"date":"2020-08-10T15:15:34","date_gmt":"2020-08-10T14:15:34","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=32928"},"modified":"2023-04-29T23:08:37","modified_gmt":"2023-04-29T22:08:37","slug":"marion-soto","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/","title":{"rendered":"Marion Soto"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Marion Soto, PhD<\/h2>\n<h4>Project leader, LNC Therapeutics<\/h4>\n\t<p>Dr.\u00a0Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris, she earned a Ph.D. in Nutrition and Neurobiology in 2014 from AgroParisTech in France. Marion was then a fellow in C. Ronald Kahn Laboratory at Joslin Diabetes Center, Harvard Medical School.<\/p>\n<p>Marion research at Harvard combined both basic science investigations and translation into clinical research, using several MRI techniques in patients with type 2 diabetes to understand how this pathology affects brain function. Her research interests also focused on how the modulations in microbiome composition associated with type 2 diabetes and obesity lead to insulin resistance in the brain and to defects in metabolism, cognition and behavior. These studies on the interactions between the microbiome and brain function show that the microbiota can regulate neurobehavioral abnormalities relevant to obesity and diabetes.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2.png\" alt=\"Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2-201x300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2-686x1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2-768x1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2-630x940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2-420x627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit_2-315x470.png 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Interactions Between Gut Microbiota and Brain in Metabolic Diseases\n\t<\/h3>\n<ul>\n<li>Gut microbiome is altered in metabolic diseases<\/li>\n<li>How the modulations in microbiome composition associated with type 2 diabetes and obesity lead to insulin resistance in the brain and to defects in metabolism. cognition and behavior<\/li>\n<li>How knowledge of the gut-brain axis crosstalk can lead to new therapeutics to treat metabolic diseases<\/li>\n<\/ul>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.lnc.bio\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.lnc.bio\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/marionsoto\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Marion Soto, PhD Project leader, LNC Therapeutics Dr.\u00a0Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris, she earned a Ph.D. in Nutrition and Neurobiology in 2014 from AgroParisTech in France. Marion was then a fellow in C. Ronald Kahn Laboratory at Joslin&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32929,"parent":32856,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-32928","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Marion Soto &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marion Soto &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-29T22:08:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/\",\"name\":\"Marion Soto &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png\",\"datePublished\":\"2020-08-10T14:15:34+00:00\",\"dateModified\":\"2023-04-29T22:08:37+00:00\",\"description\":\"Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gut-Brain Axis 2018 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Marion Soto\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marion Soto &#8226; BioTech Pharma Summit","description":"Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/","og_locale":"en_US","og_type":"article","og_title":"Marion Soto &#8226; BioTech Pharma Summit","og_description":"Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-04-29T22:08:37+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/","name":"Marion Soto &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png","datePublished":"2020-08-10T14:15:34+00:00","dateModified":"2023-04-29T22:08:37+00:00","description":"Dr. Marion Soto is leader of a project targeting the gut-brain axis at LNC Therapeutics. After graduating from the Ecole Polytechnique in Paris","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marion_Soto_LNC_Therapeutics_BioTech_Pharma_Summit.png","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/marion-soto\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Gut-Brain Axis 2018 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/"},{"@type":"ListItem","position":3,"name":"Marion Soto"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=32928"}],"version-history":[{"count":6,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32928\/revisions"}],"predecessor-version":[{"id":38248,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32928\/revisions\/38248"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32856"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/32929"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=32928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}